JP6757037B2 - ストレス評価方法 - Google Patents
ストレス評価方法 Download PDFInfo
- Publication number
- JP6757037B2 JP6757037B2 JP2018500156A JP2018500156A JP6757037B2 JP 6757037 B2 JP6757037 B2 JP 6757037B2 JP 2018500156 A JP2018500156 A JP 2018500156A JP 2018500156 A JP2018500156 A JP 2018500156A JP 6757037 B2 JP6757037 B2 JP 6757037B2
- Authority
- JP
- Japan
- Prior art keywords
- stress
- mice
- tci
- acute
- evaluation method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011156 evaluation Methods 0.000 title claims description 11
- 230000035882 stress Effects 0.000 claims description 58
- 230000037328 acute stress Effects 0.000 claims description 21
- 230000037326 chronic stress Effects 0.000 claims description 16
- 230000005856 abnormality Effects 0.000 claims description 10
- 230000003542 behavioural effect Effects 0.000 claims description 10
- HZDXFZHFEASSBM-UHFFFAOYSA-N 1,2,3,4-tetrahydrocyclopenta[b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCC2 HZDXFZHFEASSBM-UHFFFAOYSA-N 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 description 35
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 238000009395 breeding Methods 0.000 description 13
- 230000001488 breeding effect Effects 0.000 description 13
- 239000003550 marker Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000010792 Chromogranin A Human genes 0.000 description 2
- 108010038447 Chromogranin A Proteins 0.000 description 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229950009829 prasterone sulfate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016026406 | 2016-02-15 | ||
JP2016026406 | 2016-02-15 | ||
PCT/JP2017/005527 WO2017141966A1 (ja) | 2016-02-15 | 2017-02-15 | ストレス評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017141966A1 JPWO2017141966A1 (ja) | 2018-12-06 |
JP6757037B2 true JP6757037B2 (ja) | 2020-09-16 |
Family
ID=59625872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018500156A Active JP6757037B2 (ja) | 2016-02-15 | 2017-02-15 | ストレス評価方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6757037B2 (ja) |
WO (1) | WO2017141966A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA98324C2 (ru) * | 2007-04-05 | 2012-05-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
JP5964756B2 (ja) * | 2010-02-04 | 2016-08-03 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
EP2799878A1 (en) * | 2013-05-03 | 2014-11-05 | SALION GmbH | In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant using kynurenine as a marker. |
-
2017
- 2017-02-15 WO PCT/JP2017/005527 patent/WO2017141966A1/ja active Application Filing
- 2017-02-15 JP JP2018500156A patent/JP6757037B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2017141966A1 (ja) | 2018-12-06 |
WO2017141966A1 (ja) | 2017-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
van Munster et al. | Outcome measures in clinical trials for multiple sclerosis | |
Hox et al. | Occupational upper airway disease: how work affects the nose | |
Toledo et al. | CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease | |
JP5241710B2 (ja) | 神経変性障害の診断および早期診断のためのinvitroマルチパラメータ測定法 | |
Reijn et al. | CSF neurofilament protein analysis in the differential diagnosis of ALS | |
DE602007003833D1 (de) | Verbesserte vitamin-d-messung | |
Nicoletti et al. | Epilepsy and toxocariasis: a case‐control study in Burundi | |
JP4982610B2 (ja) | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー | |
JP2009515183A5 (ja) | ||
JP5687332B2 (ja) | アルツハイマー病の診断のための処方 | |
Sadoh et al. | Hepatitis B infection among Nigerian children admitted to a children’s emergency room | |
Kim et al. | Pattern difference of dissociated hand muscle atrophy in amyotrophic lateral sclerosis and variants | |
DE502006008028D1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
ZA201803854B (en) | Biomarkers for prospective determination of risk for development of active tuberculosis | |
CY1122202T1 (el) | Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης | |
JP2018004657A5 (ja) | ||
WO2014195728A2 (en) | Methods and compositions relating to neurodegenerative diseases | |
Tarlo et al. | Impact of identification of clinical phenotypes in occupational asthma | |
Béliveau et al. | Accumulation of amyloid-β in the cerebellar cortex of essential tremor patients | |
Kumar et al. | A comparative study of skin prick test versus serum-specific IgE measurement in Indian patients with bronchial asthma and allergic rhinitis | |
Poudel-Tandukar et al. | Serum albumin levels and depression in people living with human immunodeficiency virus infection: a cross-sectional study | |
JP6757037B2 (ja) | ストレス評価方法 | |
Sarsoza et al. | A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain | |
CA2541522A1 (en) | A double elisa for alzheimer's disease (ad) with applications for therapeutic vaccines to stop the disease | |
Camara‐Lemarroy et al. | Serum neurofilament‐light and glial fibrillary acidic protein levels in hydroxychloroquine‐treated primary progressive multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6757037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |